Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00712491 · ClinicalTrials.gov registry record · Phase 1

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

A Phase 1 study, sponsored by Santen.

Terminated
Registry status
Phase 1
Development phase
20
Enrollment target

NCT00712491: Clinical Trial Phase 1 study, sponsored by Santen.

NCT00712491 is a Phase 1 study that was terminated before completion, run by Santen. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00712491, a Phase 1 study, was terminated before completion, sponsored by Santen.

TERMINATED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.

Interventions

  • DRUG Sirolimus

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2008-09
Est. Completion 2010-03
Phase Phase 1
Santen

32 total trials

Why NCT00712491 stopped before completion

NCT00712491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 1 intervention - of which Sirolimus is the first listed.

NCT00712491 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00712491 about?

NCT00712491 is a clinical study titled "Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration". The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.

What is the current status of trial NCT00712491?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2008-09. Estimated completion is 2010-03.

What interventions are being tested in trial NCT00712491?

The interventions under investigation include: Sirolimus (DRUG).

Who is sponsoring clinical trial NCT00712491?

This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00712491's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00712491, the US trial registry maintained by the National Library of Medicine. NCT00712491 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.